Follow-up Discussion of Serious Adverse Event OBA Protocol Number 705

First Page		Document Content
Date: 2013-12-10 09:33:23 Clinical research Research Pharmacology Design of experiments Amgen Etanercept Clinical trial Placebo Rheumatoid arthritis Medicine Health Immunosuppressants		Follow-up Discussion of Serious Adverse Event OBA Protocol Number 705 Add to Reading List Source URL: osp.od.nih.gov Download Document from Source Website File Size: 746,99 KB Share Document on Facebook

	PROUD PROUD Participant Involvement meeting: Trial Design Date: Tuesday 9th September – 20.00 Venue: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, Holborn, WC2B 6NH Contact person: Mitzy Gaf DocID: 1vq4y - View Document
	Clinical Review & Education JAMA \| Special Communication Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols DocID: 1vmrb - View Document
	For immediate release March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infecte DocID: 1vkmw - View Document
	DEPARTMENT OF HEALTH DRUG OFFICE DRUG REGISTRATION AND IMPORT/EXPORT CONTROL DIVISION Guidance Notes on the Application for Certificate for Clinical Trial/Medicinal Test Background DocID: 1vkj3 - View Document
	CLINICAL TRIAL OUTCOME DATABASE (CTOD) Novartis RA: Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development Authors I Demin, B Hamren, O Luttringer, G Pillai and DocID: 1vbDv - View Document